Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA

Jul 19 2016

• By Derrick Gingery

SandozNorvatisDiv_1200

Related Content

Biosimilar Advisory Committee Features Actual Debate About Biosimilarity

Jul 14 2016

Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says

Jul 13 2016

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

Jul 11 2016

Sandoz’ Neulasta Biosimilar Filing Joins Another Pending At FDA

Nov 18 2015

Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Jul 15 2016

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Apr 25 2016

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

Apr 06 2016

Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit

Mar 01 2016

EU Data Helps Sandoz’s U.S. Clinical Program For Filgrastim

Jan 12 2015

Pending Biosimilars

Mar 07 2016

Sandoz Files Biosimilar Neulasta In Europe, Praises EMA

Feb 11 2016

Related Companies

Novartis AG

Amgen, Inc.

Novartis AG

Apotex Inc.

Celltrion, Inc.

Johnson & Johnson

AbbVie Inc.

Additional Topics

United States Review Pathway Regulation Drug Review Biosimilars BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window